"Bone Health Essentials: Follow-Up After Breast and Prostate Cancer" - Suzanne Bujara
For patients with cancer who received hormone-disrupting chemotherapy, improved long-term survival has come with a catch: decreased bone mineral density, according to researchers at the Icahn School of Medicine at Mount Sinai. Survivors of prostate and breast cancer and their clinicians need to monitor bone and dental health because the essential hormones used for bone remodeling have been depleted by androgen deprivation therapy and premature menopause and chemotherapy, respectively. “Androgen deprivation therapy is associated with bone loss and may lead to osteoporosis,” said co-author William Oh, MD, chief of hematology and medical oncology at the Icahn School of Medicine at Mount Sinai. “Diabetes can also contribute to bone fragility and osteoporosis, and so the two conditions may synergistically cause bone-related issues such as pain and fracture.”
— William K. Oh, MD, Professor, Medicine, Hematology, Medical Oncology, Urology, Chief, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Associate Director, Clinical Research, Tisch Cancer Institute
Loss of Radiation Therapy Clinics Could Widen Cancer Care Gaps Across the United States
Jul 10, 2026 View All Press Releases
Cancer-Associated Mutations in Brain Immune Cells May Contribute to Alzheimer's Disease
Jun 11, 2026 View All Press Releases
Reversing T Cell Exhaustion Improves Effectiveness of Myeloma Immunotherapies
May 18, 2026 View All Press Releases
